2-amino-3-(benzylcarbamothioylthio)propanoic acid | 370065-67-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-amino-3-(benzylcarbamothioylthio)propanoic acid
• 英文别名: (2-Amino-3-benzylthiocarbamoylsulfanyl)propionic acid；α-Amino-β-(N-benzylthiocarbamoylthio) propionic acid；2-azaniumyl-3-(benzylcarbamothioylsulfanyl)propanoate
• CAS: 370065-67-1
• 化学式: C₁₁H₁₄N₂O₂S₂
• mdl: MFCD00600074
• 分子量: 270.376
• InChiKey: RSTSYGXUDMJEFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• NICOTINAMIDE RIBOSIDE DERIVATIVES AND THEIR USES
  申请人：GANAPATI Gangadhara

  公开号：US20180362570A1

  公开（公告）日：2018-12-20

  The disclosure provides derivatives of both the oxidized form and the reduced form of nicotinamide riboside (NR) and nicotinic acid riboside (NAR). The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR, and can increase cellular NAD + levels and improve mitochondrial function. Therefore, the NR and NAR derivatives are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, and other disorders and conditions.

  该披露提供了烟酰胺核苷酸（NR）和烟酸核苷酸（NAR）的氧化形式和还原形式的衍生物。与NR和NAR相比，NR和NAR衍生物具有更好的稳定性和生物利用度，并且可以增加细胞NAD+水平并改善线粒体功能。因此，NR和NAR衍生物对治疗线粒体疾病、与线粒体相关的疾病和症状以及其他疾病和症状具有用处。
• NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES
  申请人：MitoPower, LLC

  公开号：US20200397807A1

  公开（公告）日：2020-12-24

  The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR. NR, NRH, NAR, NARH, and derivatives thereof can increase cellular NAD + levels and enhance mitochondrial and cellular function and cell viability. Therefore, NR, NRH, NAR, NARH, and derivatives thereof, whether alone or in combination with one or more additional therapeutic agents (e.g., a mitochondrial uncoupler or/and a PARP inhibitor), are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, metabolic disorders, and other disorders and conditions.

  该披露提供烟酰胺核糖苷（NR）、烟酰胺核糖苷的还原形式（NRH）、烟酸核糖苷（NAR）、烟酸核糖苷的还原形式（NARH）、以及它们的衍生物、组合物和用途。与NR和NAR相比，NR和NAR的衍生物具有更好的稳定性和生物利用度。NR、NRH、NAR、NARH和它们的衍生物可以增加细胞NAD+水平，增强线粒体和细胞功能以及细胞存活能力。因此，NR、NRH、NAR、NARH和它们的衍生物，无论是单独使用还是与一个或多个额外治疗剂（例如线粒体解耦蛋白抑制剂和/或PARP抑制剂）结合使用，都可用于治疗线粒体疾病、与线粒体相关的疾病和症状、代谢紊乱以及其他疾病和症状。
• N-substituted Dithiocarbamates for the Treatment of Biological Disorders
  申请人：AtheroGenics, Inc.

  公开号：US20030176496A1

  公开（公告）日：2003-09-18

  Abstract of Disclosure N-substituted dithiocarbamate esters in which the amine function bears a hydrogen are provides, as are methods for using the compounds in the treatment of cellular hyperproliferation and VCAM-1 mediated disease. Particularly provided is a method of treating a hyperproliferative disorder such as cancer comprising administering an antiproliferative agent in combination with a potentiating effective amount of a N-substituted dithiocarbamate ester. Also provided are methods of using the compounds in the treatment of VCAM-1 mediated diseases such as inflammation and carrdiovascular disease.

  本申请提供了氨基功能带有氢的N-取代二硫代氨基甲酸酯化合物，并提供了使用这些化合物治疗细胞增殖过度和VCAM-1介导疾病的方法。特别提供了一种治疗增殖过度性疾病，如癌症的方法，包括在抗增殖剂的基础上与N-取代二硫代氨基甲酸酯的增强有效量联合给药。还提供了使用这些化合物治疗VCAM-1介导疾病，如炎症和心血管疾病的方法。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• [EN] TREATMENT OF IMMUNE-RELATED DISORDERS, KIDNEY DISORDERS, LIVER DISORDERS, HEMOLYTIC DISORDERS, AND OXIDATIVE STRESS-ASSOCIATED DISORDERS USING NRH, NARH AND REDUCED DERIVATIVES THEREOF<br/>[FR] TRAITEMENT DE TROUBLES LIÉS À L'IMMUNITÉ, DE TROUBLES RÉNAUX, DE TROUBLES HÉPATIQUES, DE TROUBLES HÉMOLYTIQUES ET DE TROUBLES LIÉS AU STRESS OXYDATIF À L'AIDE DE NRH, NARH ET DE LEURS DÉRIVÉS RÉDUITS
  申请人：MITOPOWER LLC

  公开号：WO2022266322A1

  公开（公告）日：2022-12-22

  The disclosure relates to in vivo andex vivouses of dihydronicotinamide riboside (NRH), dihydronicotinic acid riboside (NARH) and reduced derivatives thereof to treat immune-related disorders (e.g., systemic inflammatory response syndrome and sepsis), kidney disorders (e.g., acute kidney injury and hepatorenal syndrome [HRS]), liver disorders (e.g., acute liver failure and HRS), hemolytic disorders (e.g., hemolysis and hemolytic anemia), and disorders and conditions associated with oxidative stress, damage or injury (e.g., methemoglobinemia and anemia). NRH, NARH and reduced derivatives thereof can be used in vivo or ex vivo alone or in combination with one or more additional therapeutic agents, such as an anti-inflammatory agent or/and an antioxidant.

  本公开涉及使用二氢烟酰胺核苷酸（NRH）、二氢烟酸核苷酸（NARH）及其还原衍生物的体内和体外应用，用于治疗免疫相关疾病（例如全身性炎症反应综合征和脓毒症）、肾脏疾病（例如急性肾损伤和肝肾综合征[HRS]）、肝脏疾病（例如急性肝衰竭和HRS）、溶血性疾病（例如溶血和溶血性贫血）以及与氧化应激、损伤或损伤相关的疾病和状况（例如高铁血红蛋白血症和贫血）。 NRH、NARH及其还原衍生物可以单独或与一个或多个其他治疗剂（例如抗炎剂或/和抗氧化剂）联合使用，进行体内或体外治疗。